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(-)-Epigallocatechin-3-gallate (EGCG) represents natural polyphenolic compounds of the plant origin. Epirubicin (EPI) 
belongs to the second generation of anthracycline drugs. The present study was undertaken to assess a possible 
influence of EGCG and/or EPI on human histiocytic lymphoma U937 cells. The in vitro research was conducted using 
the Beckman Coulter method of cell sizing, as well as flow cytometry – FSC/SSC (forward scatter/side scatter) and 
FDA/PI (fluorescein diacetate/ propidium iodide) assays. The morphological and functional changes caused in U937 
cells by each tested agent, EGCG and MAF, given alone or in combinations, were determined. The cytotoxic effects of 
(-)-epigallocatechin-3-gallate and epirubicin on human histiocytic lymphoma cells were shown. The combinations with 
EGCG enhanced the cytotoxic activity of epirubicin against U937 cells.
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INTRODUCTION
(-)-Epigallocatechin-3-gallate is the ester of 
epigallocatechin and gallic acid. EGCG is the 
most abundant and biologically active poly-
phenolic catechin in green tea Camellia sinen-
sis, Theaceae. This polyphenol compound has 
gained significant attention among scientists 
as one of the leading plant-derived molecules 
studied for its health benefits (CHEN et al., 
2004; GUPTA et al., 2008; MERELEZ and HUNSTEIN, 
2011; BANSAL et al., 2012; KANWAR et al., 2012). 
(-)-Epigallocatechin-3-gallate is a potential the-
rapeutic agent for cancer therapy (FARABEGOLI, 
2005; CARLSON et al., 2007; SHANKAR et al., 2007; 
KHAN and MUKHTAR, 2008; BLICHARSKI et al., 
2014). Elucidation of the action of EGCG, when 
applied alone or in combination with antican-
cer agents, can contribute to the development of 
more specific strategies against cancer. 
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Epirubicin (EPI) is a semisynthetic derivative 
of doxorubicin obtained by axial – to – equato-
rial epimerization of the hydroxyl group at C-4’ 
in daunosamine. EPI belongs to the second 
ge neration of anthracycline compounds with the 
improved anticancer properties. Epirubicin, an 
anthracycline drug, is primarily used for chemo-
therapy against breast and ovarian cancers, 
gastric cancer, lung cancer, and lymphomas 
(BONFANTE, 1980; HORTOBAGYI, 1997; MINOTTI et al., 
2004; NADAS and SUN, 2006; KHASRAW et al., 2012). 
An increase in the effectiveness of epirubicin is of 
key importance in anticancer therapy.
The aim of the present study was to determine 
and compare possible cytotoxic activity of (-)-epi-
gallocatechin-3-gallate and epirubicin, applied 
alone or in combinations, against human histio-
cytic lymphoma U937 cells. The morphological 
and functional changes occurring in U937 cells 
after their exposure to the action of EGCG and/
or EPI, were analyzed. 
MATERIALS AND METHODS
Cells
Human histiocytic lymphoma U937 cells 
(American Type Culture Collection, Rockville, 
MD, USA) were maintained in RPMI 1640 medi-
um (Gibco BRL Life Technologies), supplemen-
ted with 10% fetal calf serum (GIBCO BRL Life 
Technologies), 2 mM L-glutamine (Sigma Aldrich), 
and antibiotic antimycotic solution (AAS, Sigma 
Aldrich). AAS contained 20 units of penicillin, 
20 μg streptomycin and 0.05 μg amphotericin B. 
Every third day the U937 cells were passaged. 
The cells grew at 37°C in an atmosphere of 5% 
CO2 in air (HERAcell incubator, KendroLab). The 
cultures were periodically tested for Mycoplasma 
infection.
Chemicals
(-)-Epigallocatechin-3-gallate (EGCG, Sigma) and 
epirubicin hydrochloride (EPI, Bioepici n, Bioton 
S.A.) were used. EGCG and EPI were dissolved 
in 0.9% NaCl (Polpharma). All the solutions were 
freshly prepared directly before the treatment of 
the human histiocytic lymphoma U937 cells.
Agent doses and cell treatment
After diluting the cell suspension to a density of 
15×104 cells/ml medium, the U-937 cells were 
exposed simultaneously to the action of EGCG 
and EPI. Based on the unpublished data, the 
doses of the tested compounds were chosen. 
(-)-Epigallocatechin-3-gallate was given at two 
single doses of 25 μg/ml and 50 μg/ml of the 
complete RPMI 1640 medium. Epirubicin was 
applied at a single dose of 0.3 μg/ml of the com-
plete RPMI 1640 medium. Both EGCG and EPI 
were given alone and in combinations. The con-
trol material consisted of untreated U937 cells. 
Analyses of U937 cells after EGCG 
and/or EPI application
Temporary changes occurring in the human his-
tiocytic lymphoma U937 cells were analyzed at 
24h and 48h after the application of (-)-epigal-
locatechin-3-gallate and/or epirubicin. At these 
two time intervals, the mean cell volume (Fig. 1), 
cell size and granularity (Fig. 2), as well as cell 
membrane integrity (Fig. 3), were assessed. The 
research was conducted using a Coulter counter 
and FACSCalibur flow cytometer.
Cell volume measurement 
Samples of the U937 cell suspension were taken 
and immediately diluted in ISOTON II (Coulter fil-
tered electrolyte solution based on 0.9% saline, 
Beckman Coulter). 500 μl of the cell suspension 
was added to 4.5 ml of ISOTON II. Immediately 
after the dilution of the cell suspension, indi-
vidual U-937 cells were measured using the Z2 
Coulter counter (Beckman Coulter). The instru-
ment was calibrated using the Coulter CC size 
standard, 10 μm diameter latex beads (Beckman 
Coulter). Cell volume distributions of the U937 
cells were obtained using the counter equipped 
with a 100 μm diameter orifice (Beckman 
Coulter). The flow rate was 500 μl/12.5 sec. The 
range for cell measurement was determined as 
239.8-10230 fL. The cell volume was analyzed 
at 759.5-10230 fL. Using the Beckman Coulter 
method for cell sizing, the cell volume is detect-
Influence of EGCG and MAF on U937 Cells 33
ed as the amplitude of the produced electrical 
pulse which results from the passage of each 
cell through the aperture. The mean cell volume 
was determined using the Z2 AccuComp software 
(Beckman Coulter). 
Light scatter measurement 
The cell suspension was centrifuged at 1000 rpm 
(MPW-351RH centrifuge, Med. Instruments) for 
7 min at 4°C. The cell pellet was resuspended 
Fig. 1. Effects of EGCG and EPI on the U937 cell size. Representative curves for the volume distributions of U937 cells 
(A). The peaks on the left represent cellular debris, presumably apoptotic bodies and necrotic fragments, which were 
excluded from the cell volume analysis (A). The mean volume of U937 cells after their exposure to the action of EGCG 
and/or EPI (B). The obtained data are presented as mean values ± SD. Values not significantly different at P<0.05 : 
* between the groups of U937 cells treated with the tested agent(s); # compared to controls; + between the time points. 
EGCG 25 – EGCG applied at a dose of 25 μg/ml medium; EGCG 50 – EGCG given at a dose of 50 μg/ml medium; 
EPI 0.3 – EPI applied at a dose of 0.3 μg/ml medium.
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Fig. 2. Effects of EGCG and/or EPI on the light scattering properties of U937 cells. Flow cytometry analysis shows 
changes in the cell size (forward scatter, FSC on the x-axis) and granularity (side scatter, SSC on the Y-axis). Represent-
ative dot plots for U937 cells (A) and the values of FSC high/SSC low, FSC high/SSC high, and FSC low/SSC high (B). 
The obtained data (B) are presented as mean values ± SD. Values not significantly different at P<0.05 : * ** between 
the groups of U937 cells treated with the tested agent(s); # compared to controls; + between the time points. EGCG 25 
– EGCG applied at a dose of 25 μg/ml medium; EGCG 50 – EGCG given at a dose of 50 μg/ml medium; EPI 0.3 – EPI 
applied at a dose of 0.3 μg/ml medium.
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Fig. 3. Cytotoxic activity of EGCG and/or EPI against the U937 cells analyzed using the flow cytometry FDA/PI assay. 
Representative dot plots for U937 cells (A) stained with fluorescein diacetate FDA (FL1-H – fluorescence of FDA) and 
propidium iodide PI (FL3-H – fluorescence of PI), and the values of FDA+/PI-; FDA-/PI-; FDA-/PI+ (B). The obtained 
data (B) are presented as mean values ± SD. Values not significantly different at P<0.05 : * ** between the groups of 
U937 cells treated with the tested agent(s); # compared to controls; + between the time points. EGCG 25 – EGCG ap-
plied at a dose of 25 μg/ml medium; EGCG 50 – EGCG given at a dose of 50 μg/ml medium; EPI 0.3 – EPI applied at 
a dose of 0.3 μg/ml medium.
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in 500 μl of cold PBS, and forward scatter (FSC) 
and side scatter (SSC) were immediately measu-
red using a FACSCalibur flow cytometer (Becton 
Dickinson) to detect changes in the cell size and 
granularity, respectively. The flow cytometry 
FSC/SSC assay shows that the intensity of light 
scattered in the forward direction (FSC) correlates 
with the cell size, and the intensity of scattered 
light measured at a right angle to the laser beam 
(SSC) correlates with the granularity/ presence of 
intracellular structures that can reflect the light. 
The data were analyzed using the CellQuest Pro 
software (Becton Dickinson). The frequencies of 
three cell populations, FSC high/ SSC low, FSC 
high/SSC high, and FSC low/SSC high, were 
determined.
FDA/PI assay
The cell suspension containing 5×105 cells 
was centrifuged at 1000 rpm (MPW-351RH 
centrifuge, Med. Instruments) for 7 min, 
and the cell pellet was resuspended in 1 ml 
of warm HBSS (Invitrogen). Then, 10 μl of 
fluorescein diacetate (FDA) working solu-
tion (at a concentration of 1 μg/ml of HBSS) 
were added and the cells were incubated in 
the dark for 15 min at 37°C. After incubation 
with FDA, 20 μl of propidium iodide (PI) work-
ing solution (at a concentration of 30 μg/ml 
of 0.9% NaCl) was added, and the cells were 
incubated for additional 5 min. Incubation of 
cells in the presence of both FDA and PI labels 
live cells green and dying cells red. Cell samples 
were placed on ice, away from light, and FDA 
and PI fluorescence was immediately measured 
using a FACS Calibur flow cytometer. The FDA/PI 
assay of membrane integrity, using fluorescein 
diacetate, shows that this substrate, after being 
taken up by live cells, is hydrolyzed by intra-
cellular esterases. The product of the hydroly-
sis, fluorescein, is a highly fluorescent, charged 
molecule which becomes trapped in intact cells. 
Propidium iodide is excluded by an intact cell 
membrane. The data were analyzed using the 
CellQuest Pro software. The frequencies of three 
cell populations, FDA+/PI-, FDA-/PI-, and FDA-/
PI+, were determined. 
Statistical evaluation
Statistical significance of alterations in the ana-
lyzed parameters was evaluated by an analysis 
of variance and Duncan’s new multiple range 
test. A difference was considered statistically 
significant if P<0.05.
RESULTS
The cytotoxic effects of (-)-epigallocatechin-3-gal-
late and/ or epirubicin on human histiocytic 
lymphoma U937 cells were determined using the 
Beckman Coulter method of cell sizing, as well 
as flow cytometry FSC/SSC and FDA/PI assays. 
The different patterns of temporary changes in 
the mean cell volume (Fig. 1), size and granular-
ity (Fig. 2), and membrane integrity (Fig. 3) were 
observed at 24h and 48h after the application of 
EGCG, at two doses of 25 μg/ml and 50 μg/ml, 
and/or EPI at a dose of 0.3 μg/ml of medium. 
The exposure of U937 cells to the action of 
EGCG and MAF, given alone and in combina-
tions, distinctly affected the mean cell volume 
(Fig. 1). EGCG applied alone, at a higher dose, 
caused a decrease in the mean cell volume. EPI, 
given alone and in combinations with EGCG, 
caused an increase in the mean cell volume, espe-
cially at 48h after the agent(s) application. The 
influence of the combined action of catechin and 
anthracycline compouds on the U937 mean cell 
volume depended on the dose of EGCG. 
Distinct alterations in the cell size and granu-
larity of U937 cells were observed (Fig. 2). The 
exposure of U937 cells to the action of EGCG and 
EPI, applied alone and in combinations, resulted 
in a decrease in the frequency of the FSC high/ 
SSC low cell population, observed especially after 
the combined application of EPI and EGCG given 
at a higher dose. The application of catechin 
and anthracycline agents caused an increase in 
the frequency of FSC low/SSC high cell popula-
tion, especially when EGCG was given alone at 
a higher dose, and when the combination with 
EPI was used. The increased percentage values 
of FSC high/SSC high cell population were found 
after the exposure of U937 cells to the action of 
EPI, and both EGCG and EPI, and after 24h when 
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EGCG was given alone at a higher dose. The dis-
tinctly higher frequency of FSC high/SSC high 
cell population was observed at 48h, compared 
with that found at 24h after the application of EPI 
alone and in combinations with EGCG. 
The application of EGCG and EPI distinctly 
affected the membrane integrity of U937 cells 
(Fig. 3). After the exposure of U937 cells to the 
action of EGCG and EPI, given alone and in com-
binations, a decrease in the frequency of FDA+/PI- 
cell population, and an increase in the frequen-
cy FDA-/PI- population, were found. The highest 
va lues of FDA-/PI+ cell populations were observed 
at 24h after the application of EGCG alone, at 
a higher dose, and in combination with EPI. The 
highest values of FDA-/PI+ cell populations were 
found at 48h after the exposure of U937 cells to 
the action of EGCG given alone, at a higher dose, 
and in combination with EPI. The combined action 
of EPI and EGCG, given at a higher dose, caused 
the greatest reduction in the frequency of FDA+/PI- 
cell population.
DISCUSSION
In the present study, the cytotoxic activity of 
(-)-epigallocatechin-3-gallate and epirubicin 
against U937 cells was evaluated. The various 
patterns of temporary changes in the mean cell 
volume (Fig. 1), cell size, granularity (Fig. 2), and 
membrane integrity/ esterase activity (Fig. 3) 
were found at 24h and 48h after the exposure 
of U937 cells to the action of EGCG and/or EPI. 
The cytotoxic effects of EGCG and EPI on human 
histiocytic lymphoma cells were agent-, time-, and 
EGCG-dose-dependent. The effect of the com-
bined action of EGCG and EPI on the morphologi-
cal and functional alterations occurring in U937 
cells was greater than the effect of each of the 
tested agents, polyphenolic catechin and anthra-
cycline when applied alone. 
The modes of action of EGCG and EPI on the 
cells, and the precise mechanisms responsible for 
the cytotoxic effects caused by these agents are 
not fully known yet (MINOTTI et al., 2004; FENG, 
2006; KHAN et al., 2006; SINGH et al., 2011; BANSAL 
et al., 2012; KIM et al., 2014). Nevertheless, mul-
tiple mechanisms have been proposed to explain 
the cytotoxic actions of polyphenolic catechin and 
anthracycline agents. The mechanisms of action 
of (-)-epigallocatechin-3-gallate can include the 
scavenging of reactive oxygen and nitrogen species 
and chelating of redox-active transition metal ions, 
as well as production of hydrogen peroxide and 
hydroxyl radicals. The anti-oxidant or pro-oxidant 
properties of EGCG depend on its dose and the 
cell type and status (GUPTA et al., 2008; KIM et al., 
2014). EGCG can modulate several key molecu-
lar signaling pathways at multiple levels, and it 
can regulate transcription factors, DNA methyla-
tion. This polyphenolic catechin can directly inter-
act with a large set of proteins and phospholi-
pids (KHAN et al., 2006; KHAN and MUKHAR, 2008; 
SINGH et al., 2011; KANWAR et al., 2012; KIM et al., 
2014). The mechanisms of action of epirubicin, an 
anthracycline agent, include intercalation of DNA, 
inhibition of topoisomerase II activity, generation 
of free radicals with consequent interference with 
DNA, RNA and proteins (MINOTTI et al., 2004). The 
cytotoxic action of EGCG and EPI can alter the 
physiological responses of cells at molecular, bio-
chemical and morphological levels (MINOTTI et al., 
2004; FENG, 2006; KHAN et al., 2006; GUPTA et al., 
2008; KIM et al., 2014).
To sum up, the findings of the present study 
are the first available data showing the anticancer 
potential of the combined action of EGCG and EPI 
on human histiocytic lymphoma cells. A better 
understanding of the exact mechanisms of action 
of (-)epigallocatechin-3-gallate and epirubicin on 
the pathological hematopoietic cells can offer an 
opportunity for the development of improved anti-
cancer therapy.
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